Search results
Where to book a table this summer—the world's 50 top restaurants
Fortune· 1 day agoThe top five spots went to restaurants in Spain, France and Peru.
NYU and NAREIT Investor Conference Special
Skift· 2 days agoBarclays described it as uncharacteristically muted while Truist said they did not find anyone coming out swinging with the over the top bullishness they have seen in conferences in years past ...
Gene therapy trial restores hearing in both ears of children who were born deaf
Medical Xpress· 2 days agoA novel gene therapy designed to target a form of inherited deafness has restored hearing function...
China Vanke says property sales rose in May, resumes project investments
South China Morning Post· 3 days agoDebt-laden property developer China Vanke’s contracted sales rose in May in a sign the country’s...
Elon Musk accused of $7.5 billion insider trading in lawsuit from Tesla shareholder
AOL· 6 days agoTesla CEO Elon Musk was accused of insider trading in a lawsuit filed Thursday by a Tesla shareholder in Delaware Chancery Court. Shareholder Michael Perry claims in the filing that Musk sold ...
Tesla owner shares experience with one key energy feature
Teslarati· 5 days agoTesla Energy has shared its latest advertisement on social media, this time highlighting a useful...
Trojan Battery Company Introduces Trojan Lithium OnePack™ 48V Lithium-ion Battery Pack for Low-Speed...
Tehachapi News· 4 days agoTrojan Battery Company, the market leader in golf cart batteries, introduces the Trojan Lithium...
Researchers identify first step in allergic reactions, paving the way for preventative strategies
Medical Xpress· 4 days agoIt is well established that when mast cells, a type of immune cell, mistake a harmless substance, such as peanuts or dust mites, as a threat, they release an immediate first wave of bioactive ...
Surprising find could lead to drugs for severe allergic reactions
Futurity· 3 days agoThe discovery could pave way for the development of drugs to prevent these severe allergic...
AbelZeta announces clinical data showing preliminary anti-tumor activity for C-CAR031, an armored...
Morningstar· 3 days agoCAR031 study at 9.03-mo median follow up achieves disease control rate (DCR) of 91.3% and objective response rate (ORR) of 56.5% for patients across all dose levels (DLs) and ORR of 75.0% at DL4 ROCKVILLE, Md., June 4, 2024 /PRNewswire/ -- AbelZeta